Welcome to our dedicated page for Lifevantage Corporation news (Ticker: LFVN), a resource for investors and traders seeking the latest updates and insights on Lifevantage Corporation stock.
Lifevantage Corporation Common Stock (Delaware) (symbol: LFVN) is a pioneering company in the field of nutrigenomics, a cutting-edge area of nutritional science focused on how nutrients affect gene expression to improve health and wellness. Founded on the premise that aging is inevitable but can be managed, Lifevantage offers a range of products designed to combat the effects of aging and promote overall well-being.
The company's core business involves the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. Among its flagship offerings is Protandim, a scientifically-validated dietary supplement known for its ability to reduce oxidative stress. Other notable products include the LifeVantage TrueScience anti-aging skincare line, Axio energy drink mixes, PhysIQ weight management systems, and Canine Health, a pet supplement formulated to improve the health of dogs.
Lifevantage's products are available in multiple regions, including the United States, Japan, Hong Kong, Australia, Canada, the Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands. This geographical diversification helps the company reach a broad audience and sustain its growth trajectory.
Recently, Lifevantage has made significant strides in its business operations. Hundreds of independent consultants hosted virtual watch parties to kickstart the company's initiatives for 2024. The company also continues to innovate, as seen in the second quarter of fiscal 2024 results and the upcoming launch of its Evolve Compensation Plan and Rewards Circle customer loyalty program on February 1, 2024. These initiatives are designed to enhance customer satisfaction and drive business growth.
Financially, Lifevantage is committed to transparency and accountability, regularly updating investors on its performance through detailed reports and investor relations contacts. Despite the challenges posed by COVID-19, the company has maintained a resilient stance, focusing on future growth and product expansion.
Overall, Lifevantage remains a significant player in the health and wellness industry, continually advancing the science of nutrigenomics to offer effective solutions for aging and other health-related concerns.
LifeVantage Corporation (Nasdaq: LFVN) reported Q3 FY2022 results with revenues of $50.0 million, a 3.0% year-over-year decline. Total active accounts decreased by 6.5% to 157,000. Earnings per diluted share fell to $0.09 from $0.12 a year ago. The company announced a quarterly dividend of $0.03 per share. Adjusted EBITDA decreased 29.2% to $3.4 million. Fiscal 2022 revenue guidance was lowered to $204-$207 million from $212-$220 million, while adjusted EBITDA guidance was also reduced to $15 million from $18-$20 million.
LifeVantage Corporation (Nasdaq: LFVN) will release its financial results for the third quarter ending March 31, 2022, on May 3, 2022, after market close. A conference call for investors will take place at 2:30 p.m. MT (4:30 p.m. ET) on the same day. Interested participants can join via phone or a live webcast, which will also be available for replay until May 10, 2022. LifeVantage specializes in nutrigenomics, offering products like Protandim® and other dietary supplements aimed at promoting health and wellness.
LifeVantage Corporation (Nasdaq: LFVN) announced the appointment of Cindy Latham to its Board of Directors, bringing over 30 years of experience in global marketing and product development in the direct selling sector. Chairman Garry Mauro applauded her proven leadership and industry expertise, indicating a positive outlook for company growth. Latham expressed her commitment to leveraging LifeVantage's brand strength to develop new strategies. Her past roles include Chief Marketing Officer at Plexus Worldwide and Senior Vice President at Shaklee Corporation.
LifeVantage Corporation (Nasdaq: LFVN) reported Q2 fiscal 2022 results, with revenue of $52.2 million, down 11.6% YoY and 1.9% sequentially. Active accounts fell 6.3% to 163,000, driven by a 17.1% drop in the Americas. Earnings per diluted share were $0.01, compared to $0.26 last year, while adjusted EBITDA decreased 71.6% to $1.9 million. The company repurchased 0.5 million shares for $3.2 million and ended the quarter with $20.2 million in cash and no debt. Guidance for fiscal 2022 has been lowered, anticipating revenues of $212-$220 million.
LifeVantage Corporation (Nasdaq: LFVN) will announce its financial results for the second quarter ended December 31, 2021, on February 1, 2022, post-market close. A conference call for investors is scheduled for 2:30 PM MT (4:30 PM ET) the same day. Interested participants can join by dialing (877) 705-6003 or (201) 493-6725 for international callers. A replay will be available shortly after the call until February 8, 2022. LifeVantage focuses on nutrigenomics, offering products like Protandim® and Petandim®, with an emphasis on health and wellness.
LifeVantage Corporation (Nasdaq: LFVN) announced its participation in the 2022 ICR Conference on January 10 at 9:30 a.m. Eastern Time. The presentation will be accessible via a live webcast on the company's Investor Relations website.
LifeVantage specializes in nutrigenomics, focusing on how nutrition impacts health. Their product range includes dietary supplements, nootropics, and skincare. Notable products include the Protandim® family and the Axio® energy drink. For more details, visit the company's website.
LifeVantage Corporation (NASDAQ:LFVN) has launched its business in the Philippines through its subsidiary, Protandim Philippines Corporation, marking a significant step in its global expansion. The company aims to introduce wellness products, including its flagship Protandim® Nrf2 Synergizer®, to the Filipino market. LifeVantage now operates in over 20 countries and offers more than 40 health and wellness products. The CEO emphasized the company's commitment to the Filipino community and its goal of assisting individuals in creating a personal legacy.
LifeVantage Corporation (Nasdaq: LFVN) reported Q1 FY2022 results with revenue of $53.2 million, reflecting a 2.9% year-over-year decline. Active accounts dropped 4.7% to 164,000, mainly due to a 9.4% decrease in the Americas. Earnings per diluted share rose to $0.25, up 47.1%. Adjusted EBITDA decreased 13.7% to $5.8 million. The company anticipates revenue between $225 million to $235 million for FY2022 and adjusted earnings per share of $0.83 to $0.87, factoring in COVID-19 impacts.
LifeVantage Corporation (Nasdaq:LFVN) has appointed Carl Aure as its new Chief Financial Officer, effective October 25, 2021. With over 24 years in finance and accounting, Aure has significant experience in the direct selling industry, including his previous role as Chief Accounting Officer at New Age, Inc. His expertise in finance, accounting, and mergers & acquisitions is seen as crucial for LifeVantage's growth strategy. Aure expressed enthusiasm about joining the company, which specializes in nutrigenomics and aims to accelerate its growth through innovative product offerings.
LifeVantage Corporation (Nasdaq:LFVN) will release its first-quarter financial results for the period ending September 30, 2021, on November 4, 2021, after market close. A conference call for investors is scheduled for 2:30 p.m. MT (4:30 p.m. ET) on the same day. Interested participants can join via phone or through a live webcast available on the company's Investor Relations website. LifeVantage specializes in nutrigenomics and offers a range of dietary supplements and health products aimed at improving human health.
FAQ
What is the current stock price of Lifevantage Corporation (LFVN)?
What is the market cap of Lifevantage Corporation (LFVN)?
What does Lifevantage Corporation do?
What are some of the key products offered by Lifevantage?
In which regions are Lifevantage's products sold?
What recent achievements has Lifevantage made?
How does Lifevantage contribute to the field of nutrigenomics?
What is Protandim?
How does Lifevantage support its investors?
What challenges has Lifevantage faced recently?
Who should use Lifevantage products?
What is the Evolve Compensation Plan?
